Plain-English translation of NCT05554406 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether newer combinations of medications—particularly those that include —work better than the standard treatment ( and daunorubicin, known as '7+3') for newly diagnosed acute myeloid leukemia in younger adults with high-risk disease. You would be randomly assigned to receive one of five different treatment plans. The goal is to find which medication combination helps the most people achieve remission with the best quality of life.
Acute myeloid leukemia is a serious blood cancer, and the standard treatment has been used for decades. Researchers want to see if adding newer medications to the traditional chemotherapy—or using completely different combinations—can help more patients, especially those whose cancer is considered high-risk.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of five treatment groups. Each group receives a different combination of intravenous chemotherapy medications and/or oral pills given over a 28-day cycle. You will have heart imaging tests, bone marrow samples taken, and blood tests throughout the trial to see how well the treatment is working and to monitor for side effects. Most participants receive one cycle of treatment initially, and some may receive a second cycle depending on their response.
AI-generated summary from trial data · Aug 20, 2026 · Not medical advice
United States